Biontech vaccine safely protects children from covid 19 from twelve years

BionTech vaccine safely protects children from COVID 19 from twelve years

The coronavirus vaccine from biontech also protects children between 12 and 15 years ago in front of a covid 19-disease. This now shows published data, which were already the basis for the emergency in the case of the vaccine in the united states in this age group and that the european medicines agency (ema) are available for the inclusion.

In the study, more than 1000 vaccinated children and adolescents, no covid-19-case occurred, in which about the same coarse, unvaccinated control group were 16. After the vaccination, it was mostly due to slight vaccination reactions such as mutality or headaches, the scientists write in new england journal of medicine. The positive results also justified tests with young children or other, especially protective groups such as pregnant women, emphasize.

Children and adolescents usually suffered less difficult than adults, but also among them there is a serious trap, especially among children with pre-existence, writes the team around robert frenck from the cincinnati children’s hospital (us state of ohio). In addition, they played an essential role in the dissemination of the virus, their vaccination is essential to achieve herd immuneity. Finally, secure vaccines for this age group are also important for education and social development been not further hampered.

The researchers had evaluated data from a total of 2260 children between 12 and 15 years. These had received two doses of the vaccine (1131 children) or placebo syringes (1129 children) at the distance of 21 days (1129 children). For seven days after injections, the subjects noted any vaccination reactions. Unwanted effects were recorded up to six months after the second syringe.

Stable immune response

The effectiveness of a dual vaccine was the researchers at 100 percent, as there was no covid-19-case in the study group compared to the placebo group. Apart from that, laboratory tests also showed that the vaccine produced a stable immune response, it was even better than in the group of adolescents and young adults between 16 and 25 years.

As in other ages, the vaccine reactions, when they occurred, had been mild to moderate. The participants noticed pain at the puncture site, mortality, headache and fever – after the second dose more often than after the first. The complaints usually disappeared within a few days. Heavier unused effects such as thrombosis or anaphylactic shock did not occur.

The us pharmaceutical workers fda had the emergency duty for the vaccine comrishy of the german manufacturer biiontech and his us partner pfizer on 10. May on children and adolescents expanded at the age of 12 to 15 years. The european deduction has been a corresponding request since the end of april. The ema is expected to decide on this friday, a supreme is considered likely. As soon as the approval of the ema is granted, the adapted conditional in all 27 member states of the eu will be valid.

In germany, the vaccination of children and adolescents is debated. The staple vaccination commission (stiko) had indicated, despite the more likely ema-for-inclusion of the vaccine, no general vaccination recommendation for all children, but maybe only for pre-patients children. The data situation for possible side effects is still too dunn. Representatives of the medical profession exults similar concerns. Previously, federal health minister jens spahn (cdu) emphasized, after the ema-zentrlang before the beginning of the summer holidays the first children from 12 years wants to make a vaccination offer. Most recently, the federal government wants to provide nearly 6.4 million doses for vaccination of children and adolescents against the coronavirus until august. According to media reports from a document of the ministry of health for the department of the ministry of health, this.